Dextrorphan

Dextrorphan
Clinical data
Other namesDXO, Dextrorphanol
Drug classCough suppressant; NMDA receptor antagonist; Serotonin-norepinephrine reuptake inhibitor; Dissociative hallucinogen
ATC code
  • None
Legal status
Legal status
  • US: Unscheduled
Identifiers
  • (+)-17-methyl-9a,13a,14a-morphinan-3-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.004.323 Edit this at Wikidata
Chemical and physical data
FormulaC17H23NO
Molar mass257.377 g·mol−1
3D model (JSmol)
  • CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc4c3cc(O)cc4
  • InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m1/s1 X markN
  • Key:JAQUASYNZVUNQP-PVAVHDDUSA-N X markN
 X markNcheckY (what is this?)  (verify)

Dextrorphan (DXO) is a psychoactive drug of the morphinan class which acts as an antitussive or cough suppressant and in high doses a dissociative hallucinogen. It is the dextrorotatory enantiomer of racemorphan; the levorotatory enantiomer is levorphanol. Dextrorphan is produced by O-demethylation of dextromethorphan by CYP2D6. Dextrorphan is an NMDA antagonist and contributes to the psychoactive effects of dextromethorphan.

Pharmacology

Pharmacodynamics

Dextrorphan
SiteKi (nM)SpeciesRef
NMDAR
(MK-801)
486–906Rat
σ1118–481Rat
σ211,325–15,582Rat
MORTooltip μ-Opioid receptor420
>1,000
Rat
Human
DORTooltip δ-Opioid receptor34,700Rat
KORTooltip κ-Opioid receptor5,950Rat
SERTTooltip Serotonin transporter401–484Rat
NETTooltip Norepinephrine transporter≥340Rat
DATTooltip Dopamine transporter>1,000Rat
5-HT1A>1,000Rat
5-HT1B/1D54% at 1 μMRat
5-HT2A>1,000Rat
α1>1,000Rat
α2>1,000Rat
β35% at 1 μMRat
D2>1,000Rat
H195% at 1 μMRat
mAChRsTooltip Muscarinic acetylcholine receptors100% at 1 μMRat
nAChRsTooltip Nicotinic acetylcholine receptors1,300–29,600
(IC50)
Rat
VDSCsTooltip Voltage-dependent sodium channelsNDNDND
Values are Ki (nM), unless otherwise noted. The smaller the value, the more strongly the drug binds to the site.

The pharmacology of dextrorphan is similar to that of dextromethorphan (DXM). However, dextrorphan is much more potent as an NMDA receptor antagonist and much less active as a serotonin reuptake inhibitor, but retains DXM's activity as a norepinephrine reuptake inhibitor. It also has more affinity for the opioid receptors than dextromethorphan, significantly so at high doses.

Pharmacokinetics

Dextrorphan has a notably longer elimination half-life than its parent compound, and therefore has a tendency to accumulate in the blood after repeated administration of normally dosed dextromethorphan formulations.[citation needed] It is further converted to 3-HM by CYP3A4 or glucuronidated.

Society and culture

Dextrorphan was formerly a Schedule I controlled substance in the United States, but was unscheduled on October 1, 1976.

Research

Dextrorphan was under development for the treatment of stroke, and reached phase II clinical trials for this indication, but development was discontinued.

Environmental presence

In 2021, dextrorphan was identified in >75% of sludge samples taken from 12 wastewater treatment plants in California. The same study associated dextrorphan with estrogenic activity by using predictive modelling, before observing it in in vitro.

See also